Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab ...

Pfizer has terminated a Phase II study of its CD47 immune checkpoint inhibitor, maplirpacept, due to low recruitment. In an ...

Detailed price information for Icecure Medical Ltd Ord (ICCM-Q) from The Globe and Mail including charting and trades.

Oral cancer, which includes malignancies affecting the lips, tongue, gums, cheeks, and floor of the mouth, represents a ...

June brought genitourinary cancer updates, and CURE is sharing the latest in kidney cancer treatment, as well as FDA ...

According to the latest study from BCC Research, the "Cancer Immunotherapy: Technologies and Global Markets" is expected to ...

Recent oncology breakthroughs showcase innovative treatments and approvals, enhancing patient outcomes in CLL, RCC, NSCLC, ...

The study showed a >95% technical success rate when used with brush biopsy samples, a less invasive alternative to forceps ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The shift reflects more than a funding gap - it signals a structural realignment in how cancer breakthroughs may be brought to market. As public systems face pressure and timelines extend, nimble ...

This article explores how cancer biomarkers improve early detection, guide treatments and predict outcomes to transform ...